In 1993, there were 18 acute deaths in Japanese patients who had the viral disease herpes zoster and were treated with the new antiviral drug sorivudine (SRV, 1-b-D arabinofuranosyl-(E)-5-(2-bromovinyl)uracil). All the dead patients had received a 5-‰uorouracil (5-FU) prodrug as anticancer chemotherapy concomitant with SRV administration. Studies on toxicokinetics in rats and on hepatic dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme for 5-FU catabolism in rats and humans, strongly suggested that in the patients who received both SRV and the 5-FU prodrug, tissue levels of highly toxic 5-FU markedly increased as a result of irreversible inactivation of DPD in the presence of NADPH by 5-(2-bromovinyl)uracil (BVU), a metabolite formed from SRV by gut ‰ora in rats and humans. Recombinant human (h) DPD was also irreversibly inactivated by [
, and inactivates the enzyme (C). Various thiols (10 mM R SH) had no eŠect on the inactivation of hDPD (see Fig. 5 ). Panels D G represent the radioactive tryptic fragment I from the pyrimidine binding domain of hDPD labeled with [
14 C]DBEU and the increases in mass number of the peptide by the treatments with NaOH and TFA (see Fig. 6 ). The deduced amino acid sequence of hDPD 10) is aligned with amino acid sequences of DPDs cloned from the bovine, 11) porcine 10) and rat 12) DPDs and of putative DPD encoded in the C. elegance gene 13) and a DPD like peptide in the D. melanogaster mRNA. 14) Identical amino acid residues to those in the sequence of hDPD are represented by dashes. Arabic numerals represent amino acid positions counted from the leading amino acid Met. Our proposal for the pyrimidine binding domain ( A part of dosed SRV is decomposed to BVU by gut ‰ora in the intestines, absorbed through the intestinal membrane, and carried into the liver having potent activity of DPD. BVU is reduced to reactive dihydro BVU (DBEU) with NADPH in the pyrimidine binding domain of DPD, reacts with Cys671 located at the substrate binding domain, and inactivates the enzyme. Inactivation of hepatic DPD leads rats and humans to poor 5-FU metabolizers and, consequently, increases the tissue 5-FU levels markedly. Acute deaths in patients administered with SRV and FT are most likely to be attributable to the severe toxicity to bone marrow by the markedly elevated levels of 5-FU. 
